Lyell Immunopharma (LYEL) Financials: Revenue & Earnings

LYEL price $10.47 +0.35 +3.44%

Ticker
LYEL
Price
$10.47
Change
+0.35 +3.44%
Market cap ?
$256.52M
P/E ?
-0.59
Dividend yield ?
0.00%
Beta ?
-0.07
Sector
Healthcare
Industry
Biotechnology

Financials

2019202020212022202320242025
657000775600010650000846830001300006100036000

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company’s lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical…

Fair value

LYEL fair value Not meaningful. Price $10.47.

Fair value is an estimate of what one share is worth if future cash flows arrive as modeled. It is not a forecast of the share price. How discounted cash flow works.

Not meaningful

Compare LYEL

Earnings

DateEPS actualEPS estimateRevenueRevenue estimate
2026-11-10—-2.06—4.60K
2026-08-06-1.92-1.904.00K3.62K
2026-05-06-1.10-2.782.00K3.00K
2026-03-12-7.68-2.156.00K15.25K
2025-11-12-2.13-2.8115.00K5.00K
2025-08-12-2.89-3.808.00K4.00K
2025-05-13-3.60-3.607.00K7.00K
2025-03-11-14.40-3.4011.00K—
2024-11-07-3.40-0.2034.00K—
2024-08-07-3.60-4.0013.00K3.25K
2024-05-06-4.80-4.003.00K1.00K
2024-02-28-4.00-4.2013.00K3.25K
2023-11-07-4.00-4.8425.00K6.25K
2023-08-08-5.20-5.2527.00K18.00K
2023-05-04-0.23-0.3165.00K-17.50K
2023-02-28-0.03-0.3148.39M16.13M
2022-11-08-0.28-0.343.00K1.80M
2022-08-04-0.15-6.2035.74M17.87M
2022-05-10-0.28-0.29553.00K776.50K
2022-03-29-0.35-0.272.82M2.64M
2021-11-12-0.20-5.402.75M3.47M
2021-08-12-0.89-0.362.63M2.63M
2021-06-18-0.16-7.502.31M2.31M
2020-09-30-0.17—1.07M—
2020-06-30-0.48—3.12M—
2020-03-31-0.14—1.26M—

Dividends

Yield 0.00%. Payout ratio 0.00%. Frequency —.

Safety score 37/100 · Watch. Payout ratio is 0% of earnings. Free-cash-flow coverage is not available, so this part stays neutral. No dividend history was found. There is no dividend yield.

Ex-dateDividendRecordPaymentFrequency
No data yet.

Insider trades

DateInsiderActionSharesPriceValue
2026-10-12Aguirre Jarrad MattieuSell422$8.633.64K
2026-09-10Shook DavidSell500$12.706.35K
2026-09-10Aguirre Jarrad MattieuBuy47.50K$12.20579.50K
2026-08-31Aguirre Jarrad MattieuOther0——
2026-08-31Aguirre Jarrad MattieuOther46.25K$11.64538.34K
2026-08-31Aguirre Jarrad MattieuOther35.00K$23.71829.85K
2026-08-31Aguirre Jarrad MattieuOther15.00K$19.20288.00K
2026-08-21Seely LynnSell9.59K$15.54149.01K
2026-08-21Hill Stephen J.Sell989$15.5415.37K
2026-08-21Lee Gary K.Sell1.46K$15.5422.64K
2026-08-10Bulis Veronica SanchezSell621$14.348.91K
2026-08-10Lee Gary K.Sell131$14.341.88K
2026-08-10Hill Stephen J.Sell89$14.341.28K
2026-08-10Seely LynnSell390$14.345.59K
2026-07-27Innovative Cellular Therapeutics Holdings LtdSell44.00K——
2026-07-27Innovative Cellular Therapeutics Holdings LtdSell38.50K——
2026-07-17Innovative Cellular Therapeutics Holdings LtdSell10$13.70137
2026-07-16Innovative Cellular Therapeutics Holdings LtdSell10$13.73137
2026-06-29Innovative Cellular Therapeutics Holdings LtdSell76.00K——
2026-06-15Innovative Cellular Therapeutics Holdings LtdSell66.50K——
2026-06-10RIEFLIN WILLIAM JLBuy9.25K$13.22122.28K
2026-06-10Ramachandra SumantBuy9.25K$13.22122.28K
2026-06-10NABEL ELIZABETH GBuy9.25K$13.22122.28K
2026-06-10Klausner RichardBuy9.25K$13.22122.28K
2026-06-10FRIEDMAN CATHYBuy9.25K$13.22122.28K
2026-06-10BRAWLEY OTIS WBuy9.25K$13.22122.28K
2026-06-10Bachleda MarkBuy9.25K$13.22122.28K
2026-06-10Shook DavidSell1.98K$12.6424.99K
2026-05-18Innovative Cellular Therapeutics Holdings LtdOther0——
2026-05-11Seely LynnSell388$18.917.34K
2026-05-11Lee Gary K.Sell130$18.922.46K
2026-05-11Hill Stephen J.Sell89$18.921.68K
2026-05-11Bulis Veronica SanchezSell217$18.914.10K
2026-03-09Shah SmitalBuy140.00K$25.503.57M
2026-03-09Shah SmitalOther0——
2026-03-06ARCH Venture Partners IX, LLCBuy488.09K$25.6112.50M
2026-03-06ARCH Venture Fund XIII, L.P.Buy488.09K$25.6112.50M
2026-02-11Seely LynnSell7.46K$23.39174.37K
2026-02-11Hill Stephen J.Sell1.24K$23.3928.91K
2026-02-11Lee Gary K.Sell1.67K$23.3939.08K
2026-02-10Hill Stephen J.Buy65.00K$23.711.54M
2026-02-10Hill Stephen J.Sell109$23.122.52K
2026-02-10Lee Gary K.Buy50.00K$23.711.19M
2026-02-10Lee Gary K.Sell147$23.123.40K
2026-02-10Seely LynnBuy155.00K$23.713.68M
2026-02-10Seely LynnSell438$23.1210.13K
2026-02-10Meltz Mark ABuy50.00K$23.711.19M
2026-02-10Bulis Veronica SanchezBuy8.75K——
2026-02-10Bulis Veronica SanchezSell254$23.125.87K
2026-02-10Shook DavidBuy50.00K$23.711.19M
2026-02-09Hill Stephen J.Buy4.00K——
2026-02-09Lee Gary K.Buy4.00K——
2026-02-09Seely LynnBuy20.00K——
2025-12-30Bulis Veronica SanchezSell936$32.3230.25K
2025-12-24Bulis Veronica SanchezSell1.14K$38.6743.93K
2025-11-10Seely LynnSell412$16.116.64K
2025-11-10Bulis Veronica SanchezSell239$16.103.85K
2025-11-10Lee Gary K.Sell138$16.162.23K
2025-11-10Hill Stephen J.Sell95$16.121.53K
2025-10-31Bulis Veronica SanchezOther0——
2025-10-31Bulis Veronica SanchezOther1.67K$42.6071.31K
2025-10-31Bulis Veronica SanchezOther3.00K$37.40112.20K
2025-10-27Hill Stephen J.Buy75.00K$17.231.29M
2025-10-27Lee Gary K.Buy68.00K$17.231.17M
2025-10-27Seely LynnBuy175.00K$17.233.02M
2025-08-21Seely LynnSell7.26K$10.5476.52K
2025-08-21Hill Stephen J.Sell1.00K$10.5410.59K
2025-08-21Newton Charles W.Sell1.45K$10.5415.32K
2025-08-21Lee Gary K.Sell1.45K$10.5415.32K
2025-08-20Seely LynnBuy40.00K——
2025-08-20Hill Stephen J.Buy8.00K——
2025-08-20Newton Charles W.Buy8.00K——
2025-08-20Lee Gary K.Buy8.00K——
2025-08-12Seely LynnSell406$10.344.20K
2025-08-12Hill Stephen J.Sell94$10.34972
2025-08-12Lee Gary K.Sell136$10.341.41K
2025-08-12Newton Charles W.Sell136$10.341.41K
2025-08-11Seely LynnSell391$10.534.12K
2025-08-11Hill Stephen J.Sell91$10.53958
2025-08-11Lee Gary K.Sell131$10.531.38K
2025-08-11Newton Charles W.Sell131$10.531.38K
2025-07-25ARCH Venture Partners IX, LLCOther0——
2025-07-25ARCH Venture Fund XIII, L.P.Other0——
2025-06-09Bachleda MarkBuy13.00K$12.47162.11K
2025-06-09Meltz Mark ABuy100.00K$12.471.25M
2025-06-09Shook DavidBuy43.75K$12.47545.56K
2025-06-09Shook DavidBuy21.90K——
2025-06-09Bachleda MarkOther0——
2025-06-09Meltz Mark AOther0——
2025-06-09Shook DavidOther0——
2025-05-15Klausner RichardBuy130.00K$0.4052.22K
2025-05-15RIEFLIN WILLIAM JLBuy130.00K$0.4052.22K
2025-05-15FRIEDMAN CATHYBuy130.00K$0.4052.22K
2025-05-15BRAWLEY OTIS WBuy130.00K$0.4052.22K
2025-05-15NABEL ELIZABETH GBuy130.00K$0.4052.22K
2025-05-15Ramachandra SumantBuy130.00K$0.4052.22K
2025-03-31BRAWLEY OTIS WBuy35.64K$0.5619.96K
2025-03-21Ramachandra SumantBuy200.00K$0.58115.22K
2025-03-17Newton Charles W.Buy200.00K$0.56111.62K
2025-03-14Klausner RichardBuy158.00K$0.6094.94K

Institutional holders

Latest filed quarter: Q2 2026.

Institutions holding: 91, holders +15 vs prior quarter. Ownership 51.75%.

HolderSharesChangeChange %Value
ARCH VENTURE MANAGEMENT, LLC3.25M00.00%45.53M
GSK PLC1.51M00.00%21.25M
VANGUARD CAPITAL MANAGEMENT LLC786.77K68.62K+9.55%11.05M
ORLAND PROPERTIES LTD754.70K00.00%10.60M
BLACKROCK, INC.724.34K532.52K+277.62%10.18M
ALMITAS CAPITAL LLC581.41K3.60K+0.62%8.17M
FORESITE CAPITAL MANAGEMENT V, LLC476.39K-692-0.15%6.69M
MILLENNIUM MANAGEMENT LLC367.47K-91.43K-19.92%5.16M
OPALEYE MANAGEMENT INC.344.02K264.93K+334.94%4.83M
VENBIO PARTNERS LLC337.70K00.00%4.74M
GEODE CAPITAL MANAGEMENT, LLC310.64K143.66K+86.03%4.37M
ALPHABET INC.293.26K00.00%4.12M
STATE STREET CORP185.32K112.80K+155.54%2.60M
HSG HOLDING LTD152.30K00.00%2.14M
RENAISSANCE TECHNOLOGIES LLC130.19K13.78K+11.84%1.83M
NORTHERN TRUST CORP118.50K88.22K+291.35%1.66M
QUBE RESEARCH & TECHNOLOGIES LTD110.53K55.42K+100.56%1.55M
CHARLES SCHWAB INVESTMENT MANAGEMENT INC107.57K21.60K+25.12%1.51M
SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P.107.57K107.57KNew1.51M
MARSHALL WACE, LLP106.30K-42.22K-28.43%1.49M
VELAN CAPITAL INVESTMENT MANAGEMENT LP105.00K3.00K+2.94%1.48M
VANGUARD FIDUCIARY TRUST CO93.09K6.17K+7.10%1.31M
VANGUARD PORTFOLIO MANAGEMENT LLC91.89K68.88K+299.27%1.29M
MIC CAPITAL MANAGEMENT UK LLP87.03K00.00%1.22M
GOLDMAN SACHS GROUP INC86.78K-27.71K-24.20%1.22M

Earnings and financials

Lyell Immunopharma, Inc. (LYEL) trades at $10.47, with a market cap of $256.52M and a trailing P/E of -0.59. Revenue below is the annual history on file. It describes what the business has already reported. It is not a forecast and it is not a recommendation.

Financials

2019202020212022202320242025
657000775600010650000846830001300006100036000

Insights · Dividends · Forecast · Financials · Learn

Stocklytics home · Screener

Lyell Immunopharma (LYEL) Financials: Revenue & Earnings

LYEL$10.47+0.35 +3.44%

$256.52M

Market Cap

-0.59

P/E

—

Forward P/E

—

Score

Price History